Research map: Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence

Back to the article

Papers in this map

  1. Tissue-based map of the human proteome · Mathias Uhlén · 2015 · 16361 citations · Cited by this paper
  2. Association of different approvals with Chinese Society of Clinical Oncology recommendation levels for solid tumor drugs: a cross-sectional analysis · 2025 · Related
  3. Towards a knowledge-based Human Protein Atlas · Mathias Uhlén · 2010 · 2549 citations · Cited by this paper
  4. Clinical potential of antibody–drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors · 2025 · Related
  5. Recent advances in twisted intramolecular charge transfer (TICT) fluorescence and related phenomena in materials chemistry · Shunsuke Sasaki · 2016 · 1201 citations · Cited by this paper
  6. Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer · 2025 · Related
  7. Tissue Processing and Hematoxylin and Eosin Staining · Ada T. Feldman · 2014 · 1101 citations · Cited by this paper
  8. A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors · 2026 · Related
  9. Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker · Flavio Solca · 2012 · 880 citations · Cited by this paper
  10. Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy · 2025 · Related
  11. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies · Zhenyi An · 2018 · 691 citations · Cited by this paper
  12. Crocetin suppresses colorectal cancer progression by targeting TGM2 and inhibiting the JAK2/STAT3 pathway · 2026 · Related
  13. A Perspective on the Kinetics of Covalent and Irreversible Inhibition · John M. Strelow · 2016 · 388 citations · Cited by this paper
  14. ABCB1 and ABCC10 polymorphisms predict sensitivity to first- and third-generation EGFR-TKIs in EGFR-mutant NSCLC · 2025 · Related
  15. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance · Phillip A. Schwartz · 2013 · 285 citations · Cited by this paper
  16. Class-level DILI saturation and hERG-driven risk stratification among 2024–2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis · 2026 · Related
  17. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling · Keren Shtiegman · 2007 · 160 citations · Cited by this paper
  18. Selective cytotoxicity of solamargine via oxidative stress and caspase-independent mechanisms in human glioblastoma cells · 2026 · Related
  19. Synthesis and Photophysical Studies of a Series of Quinazoline Chromophores · Sylvain Achelle · 2014 · 134 citations · Cited by this paper
  20. Patient-derived tumor organoids for new drug development: promises and challenges · 2026 · Related
  21. Kinetics and Thermodynamics of Phalloidin Binding to Actin Filaments from Three Divergent Species · Enrique M. De La Cruz · 1996 · 98 citations · Cited by this paper
  22. Assay validation for the assessment of adipogenesis of multipotential stromal cells—a direct comparison of four different methods · Andrew Robert Aldridge · 2013 · 70 citations · Cited by this paper
  23. DAPI binding to the DNA minor groove: a continuum solvent analysis · Luis Felipe Pineda De Castro · 2002 · 62 citations · Cited by this paper
  24. Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer · Yongjie Huang · 2018 · 62 citations · Cited by this paper
  25. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence · Xiaochun Wang · 2016 · 54 citations · Cited by this paper
  26. EGFR Activation Leads to Cell Death Independent of PI3K/AKT/mTOR in an AD293 Cell Line · Cezary Treda · 2016 · 41 citations · Cited by this paper
  27. A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations · Hui Deng · 2022 · 38 citations · Cited by this paper
  28. Emission Tuning of Fluorescent Kinase Inhibitors: Conjugation Length and Substituent Effects · Jyothi Dhuguru · 2014 · 35 citations · Cited by this paper
  29. Binding-induced, turn-on fluorescence of the EGFR/ERBB kinase inhibitor, lapatinib · James N. Wilson · 2015 · 29 citations · Cited by this paper
  30. Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes · Wojciech J. Stec · 2016 · 29 citations · Cited by this paper
  31. Characterization of Covalent-Reversible EGFR Inhibitors · Steven P. Smith · 2017 · 29 citations · Cited by this paper
  32. Low Incidence along with Low mRNA Levels of EGFRvIII in Prostate and Colorectal Cancers Compared to Glioblastoma · Joanna Peciak · 2017 · 18 citations · Cited by this paper
  33. Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations · Min Peng · 2018 · 10 citations · Cited by this paper
  34. Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy · Cezary Tręda · 2023 · 9 citations · Cited by this paper
  35. Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding · Pasquale A. Morese · 2025 · 7 citations · Cited by this paper
  36. Fluorescence phenomena in nerve-labeling styryl-type dyes · Tiberiu M. Siclovan · 2015 · 3 citations · Cited by this paper
  37. Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent · Nahid Golabi · 2020 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)